Landos’ advanced AI-based integrated computational LANCE platform explores immune cell activity and metabolic function, a distinct approach that has verified two novel pathways currently in clinical development: LANCL2 and NLRX1. Activation of the LANCL2 pathway amplifies the immunosuppressive functions of T regulatory cells while decreasing production of inflammatory cytokines such as TNF-alpha. NLRX1, a second pathway discovered by Landos, provides a mechanism for modulating immune functions to complement or act in combination with other related treatments.
Identifying Novel
Pathways at the
Interface of Immunity
and Metabolism
We are committed to
the discovery and
development of
first-in-class, oral
therapeutics for
patients with
autoimmune disease
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. The Company’s lead product candidate, omilancor (BT-11), is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.
In January 2021, the Company reported initial results from its Phase 2 trial of omilancor for patients with mild to moderate ulcerative colitis (UC). In the first half of 2021, Landos expects to initiate a Phase 3 trial of omilancor in UC patients and plans to initiate a Phase 2 trial of omilancor in moderate to severe Crohn’s disease (CD).
Reprogramming Immune Responses in Autoimmune Disease
Aiming to Bring Safer,
More Effective
Therapies to Patients
with IBD
For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Landos’ therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.
At Landos Biopharma, our mission is to
be bold and uncover new mechanisms of
treating autoimmune disease.
News
4/13
Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors
Read More4/6
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
Read More3/4
Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers
Read More